1 Relationship between branched chain amino acids and type 2 diabetes: a bidirectional

2 Mendelian Randomization study

- 3
- 4 Jonathan D. Mosley^{1,2*}, Mingjian Shi^{1*}, David Agamasu³, Nataraja Sarma Vaitinadin, PhD²,
- 5 Venkatesh Murthy⁴, Ravi V. Shah², Minoo Bagheri², Jane F. Ferguson²
- 6 *Contributed equally.
- 7
- 8 1) Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN,
- 9 USA; 2) Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA;
- 10 3) Meharry Medical College, Nashville, Tennessee, USA; 4) Division of Cardiovascular
- 11 Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI
- 12

13 Address for correspondence:

- 14 Jonathan D. Mosley, M.D., Ph.D.
- 15 Associate Professor of Medicine and Biomedical Informatics
- 16 Vanderbilt University Medical Center
- 17 1285 Medical Research Building IV
- 18 Nashville, TN 37232
- 19 Telephone: 615-875-2965; Fax: 615-343-4522; E-mail: jonathan.d.mosley@vumc.org
- 20
- 21 Keywords: Branched chain amino acids, type 2 diabetes, Mendelian randomization, insulin
- 22 resistance, body mass index
- 23

24 ABSTRACT

25	Background: Human genetic studies suggest that the branched chain amino acids (BCAA)
26	valine, leucine and isoleucine have a causal association with type 2 diabetes. However,
27	inferences are based on analyses of a limited number of genetic loci associated with BCAAs.
28	Whether these conclusions are supported when using instrumental variables for BCAAs that
29	capture a broad set of genetic mechanisms is not known. Methods: We constructed and
30	validated instrumental variables for each BCAA using large well-powered datasets and tested
31	their association with type 2 diabetes using the two-sample inverse variance weighted (IWV)
32	Mendelian randomization (MR) approach. Sensitivity analyses were performed to ensure the
33	accuracy of the findings. Instrumental variables for type 2 diabetes, fasting insulin and body
34	mass index (BMI) were also tested for associations with BCAA levels. Results: There were no
35	significant associations with diabetes for valine (beta=0.17 change in log-odds per standard
36	deviation change in valine, [95% CI, -0.28 - 0.62], p=0.45), leucine (beta=0.19 [-0.30 - 0.68]
37	p=0.45) or isoleucine (beta=0.02 [-0.54 - 0.59], p=0.94). In contrast, type 2 diabetes was
38	associated with each BCAA (valine: beta=0.08 per standard deviation change in levels per log-
39	odds change in type 2 diabetes, [0.05 - 0.10], p=1.8x10 ⁻⁹), (leucine: beta= 0.06 [0.04 - 0.09],
40	$p=4.5x10^{-8}$) and isoleucine (beta= 0.06 [0.04 - 0.08], $p=2.8x10^{-8}$). The type 2 diabetes
41	associations were replicated in an independent population, but not in a second population where
42	type 2 diabetes cases were removed, highlighting the consistency and specificity of the
43	association. Similar positive associations were seen for fasting insulin and BMI with the BCAAs.
44	In multivariable MR analyses, type 2 diabetes and fasting insulin had consistent independent
45	associations with each BCAA. Conclusions: These data suggest that the BCAAs are not
46	mediators of type 2 diabetes risk but are biomarkers of diabetes and higher insulin.

47 **INTRODUCTION**

The branched chain amino acids (BCAA) valine, leucine and isoleucine are essential amino acids 48 with functional roles that include regulation of lipid, glucose and protein metabolism.¹ It has long 49 50 been recognized that BCAA levels in blood are elevated in individuals with impaired insulin 51 secretion and obesity.² These early observations have prompted interest as to whether the 52 BCAAs may have an etiological role in insulin resistance and metabolic disease, including type 2 53 diabetes. Human studies suggesting roles for the BCAAs as upstream drivers of metabolic 54 disease include a prospective study of normoglycemic participants that found individuals with the highest baseline BCAA levels were at 5-fold increased risk of incident diabetes.³ However, 55 findings from epidemiological studies have not been consistent in all populations.^{4–8} 56 57 58 Support for an etiological role of the BCAAs in the development of type 2 diabetes has also 59 come from human genetics studies. Genetic methodologies, such as Mendelian randomization, 60 use single nucleotide polymorphisms (SNPs) as instrumental variables to determine whether an exposure may have a causal association with an outcome.⁹ An advantage of these studies is that 61 62 they can be less prone to biases such as reverse causation, which can lead to incorrect inferences in epidemiological studies.¹⁰ One study focused largely on SNPs flanking the gene *PPM1K*, 63 64 which encodes a protein phosphatase which activates the branched chain α -ketoacid 65 dehydrogenase complex (BCKDC) that catalyzes the first irreversible step in the BCAA metabolism.¹¹ The investigators identified a significant positive association between genetically 66 67 predicted BCAA levels and type 2 diabetes risk, suggesting that BCAAs are upstream mediators of risk.¹² A subsequent study examined 3 genetic instruments near the *PPM1K*, *SLC1A4*, *ASGR1* 68 69 genes and did not find an association with Homeostatic Model Assessment for Insulin Resistance

70	(HOMA-IR). ¹³ Rather they found a polygenic predictor of HOMA-IR was positively associated
71	with the BCAAs, suggesting that the BCAAs are elevated as a consequence of insulin resistance.
72	These results were supported by a later study showing a positive association between genetic
73	predictors of insulin resistance phenotypes and BCAAs. A common unifying interpretation of
74	these findings is that BCAAs may be the causal down-stream mediators linking insulin resistance
75	and obesity phenotypes to type 2 diabetes risk. ^{12,14}
76	
77	A limitation of the prior genetic studies is that they examined a small number of genetic loci
78	associated with BCAA levels, thereby limiting the strength of evidence for a causal role of the
79	BCAAs on type 2 diabetes. Recent large-scale genome-wide association studies (GWAS) of
80	BCAAs have identified considerably more genetic loci associated with the BCAAs, providing an
81	opportunity to investigate etiological relationships using robust predictors that represent
82	heterogenous genetic mechanisms modulating BCAA levels. ¹⁵ We developed genetic
83	instruments for the BCAAs and metabolic phenotypes using data derived from contemporary
84	large-scale GWAS and applied Mendelian randomization approaches to define the relationships
85	among these phenotypes.
86	
87	
88	METHODS

89 **GWAS Summary Statistics data sets**

90 Single nucleotide polymorphisms (SNPs) associated with valine, leucine and isoleucine used in

- 91 the primary analyses were derived from GWAS summary statistics generated by a study
- 92 examining 115,082 UK Biobank European Ancestry participants with NMR metabolomics from

93	Nightingale Health (biomarker quantification version 2020). ¹⁵ Prior to GWAS, metabolite levels
94	were inverse rank-normalized and set to a standard deviation of 1. Data were downloaded from
95	the NHGRI-EBI GWAS Catalog (GCST90092891, GCST90092843, GCST90092995). ¹⁶ GWAS
96	summary statistics used for validation of SNP genetic instruments were obtained from the
97	Metabolic Syndrome in Men (METSIM) consortium, a study of 6136 Finnish men without
98	prevalent or incident type 2 diabetes and with metabolites measured using the relative
99	quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) Metabolon
100	DiscoveryHD4 platform. ¹⁷ Metabolite level residuals were inverse-normalized and summary
101	statistics were downloaded from https://pheweb.org/metsim-metab/. Summary statistics were
102	also obtained a study of 7,824 European ancestry participants from the TwinsUK and
103	Cooperative Health Research in the Region of Augsburg (KORA) cohort who underwent
104	metabolite acquisition by Metabolon using GC-MS or UPLC-MS/MS. Summary statistics based
105	on log10 transformed metabolite levels were obtained from http://metabolomics.helmholtz-
106	muenchen.de/gwas/. ¹⁸
107	
108	Summary statistics for type 2 diabetes from a study of 898,130 cases and controls of European
109	ancestry were obtained from the DIAGRAM consortium (https://diagram-
110	consortium.org/downloads.html. ¹⁹ Summary statistics were from a subset of the cohort that did
111	not include the UK Biobank population. Summary statistics of log-transformed fasting insulin
112	from a study of 151,188 individuals of European ancestry without type 2 diabetes ²⁰ were
113	obtained from the MAGIC consortium (https://magicinvestigators.org/downloads/). Summary
114	statistics for body mass index (BMI) were from a study of 339,224 adults of European ancestry
115	and obtained from the GIANT consortium

116 (https://	portals.	broadin	stitute.or	g/col	llaborati	on/gia	nt/index	.phr	o/GIAN	JT	consortium_	data	files)	.2
110 (incep D.	por carb.	oroaam	5010010101		ind of all	on Sia	10 1110011	• • • • • •		<u>،</u>	combol mani-	_aaaa_		•

- ¹None of these data sets included participants from the UK Biobank to ensure there was no
- 118 overlap with the UK Biobank metabolite cohort.
- 119
- 120 Analysis

121 Lead SNP identification

- 122 Lead SNPs associated with valine, leucine and isoleucine were selected from the UK Biobank
- summary statistics using a clumping algorithm that selected a linkage disequilibrium (LD)-
- reduced set of SNPs (r-squared <0.001, selection window of 3000 Kb) and a minor allele
- 125 frequency (MAF) >1%.
- 126

127 Annotation

- 128 The FUMA webserver (https://fuma.ctglab.nl/), with default settings, was used to identify nearby
- 129 genes and expression QTLs (based on GTEx v8.0) associated with candidate SNPs.²² The
- 130 DAVID program was used to identify ontologies, cellular locations and pathways associated
- 131 with candidate genes.^{23,24} These data in conjunction with a manual literature review was used to
- 132 identify the likely candidate genes located near associated SNPs. If a single likely candidate gene
- 133 could not be identified, all plausible candidate genes are presented. Visualization of the cellular
- 134 locations of candidate genes were created with BioRender.com.

135

136 Mendelian Randomization

137 Mendelian randomization (MR) approaches were used to test associations between genetic

138 instruments for the BCAAs and outcomes. MR is an analytic framework that uses SNPs

139	associated with diverse pleiotropic mechanisms as instrumental variables to test the association
140	between an exposure and outcome. ^{9,10} The validity of the approach relies on the following
141	assumptions: (1) Relevance: the SNP instrumental variables are associated with the exposures;
142	(2): Independence: the instrumental variables are not associated with confounders; and (3)
143	Exclusion restriction: the instrumental variables association with the outcome is only through the
144	exposure. ²⁵ We demonstrate the relevance assumption by validating that our BCAA genetic
145	instruments associated with their corresponding BCAAs in an independent population. We
146	conducted a range of MR sensitivity analyses, as well as multivariable analyses to decrease the
147	likelihood of violating the other assumptions.
148	
149	SNP genetic instruments were constructed for each BCAA from the UK Biobank GWAS. Non-
150	palindromic common (MAF>5%) SNP instruments were selected using a clumping algorithm
151	and SNPs that were available on each set of summary statistics for the METSIM BCAAs, type 2
152	diabetes and fasting insulin levels. Two-sample MR approach was used to test the association
153	between BCAA and outcome (the corresponding BCAA in METSIM and type 2 diabetes) using
154	inverse-variance weighted regression (IVW). ²⁶ The Cochran's Q statistic and its associated p-
155	value, was used to assess for horizontal pleiotropy, and p<0.05 was deemed suggestive of
156	pleiotropy. In addition, sensitivity analyses were performed using MR-Egger to assess for
157	horizontal pleiotropy and the weighted median method. ^{27,28} A leave-one-out analyses was also
158	performed for the BCAA/type 2 diabetes associations. Associations were tested using the
159	Mendelian Randomization R package. ²⁹ MR-PRESSO was used to assess for horizontal
160	pleiotropy (global test) and distortions in IVW estimates (distortion test) with exclusion of SNPs
161	identified as outliers at p<0.05/(# of genetic instruments). ³⁰

162	The same MR approaches were used to assess whether instrumental variables for type 2 diabetes,
163	fasting insulin and BMI were associated with each BCAA. The association between type 2
164	diabetes and each BCAA was also examined using metabolites measured in the KORA and
165	METSIM studies.
166	Pairwise multivariable MR (MVMR) was used to test for whether the associations between type
167	2 diabetes and the BCAAs was independent of fasting insulin and BMI.
168	All statistical tests were two-sided and a nominal p< 0.05 was considered significant. ³¹
169	
170	
171	RESULTS
172	We identified independent common SNPs (MAF>1%) significantly associated ($p < 5x10^{-8}$) with
173	the BCAAs from GWAS performed on 115,082 European Ancestry UK Biobank participants.
174	There were 18, 15 and 8 associated SNPs for valine, leucine and isoleucine, respectively (Table
175	1 and Supplemental Table 1). Five SNPs were located near genes examined in prior BCAA
176	association studies (GCKR, PPM1K, DDX19A, SLC1A4 and ASGR1 [which is near
177	<i>SLC2A4</i>]). ^{12,13} Two associations were near gene loci that have direct roles in BCAA metabolism
178	(PPM1K, BCAT2), while others had known functionality related to intermediate metabolism
179	(SLC1A4, PRODH, GLS2, GLUD1, PCCB), insulin signaling (IRS1, GRB14, GCKR) and
180	glucose regulation (GCKR, SLC2A4) (Figure 1). HNF4G and RLN3 have previously been
181	associated with adiposity traits. We did not observe associations previously reported near
182	<i>TRMT61A</i> and <i>CBLN1</i> in the UK biobank or METSIM cohorts (Supplemental Table 2). ¹²
183	We constructed genetic instruments for each BCAA in the UK Biobank set (Supplemental
184	Table 3). To validate these predictors, we tested their associations with corresponding BCAAs

185	measured in the METSIM data set. Effect sizes for each SNP instrument were generally linearly
186	related for each BCAA between the studies (Figure 2), and MR analyses demonstrated
187	significant (p<0.05), positive associations for each BCAA, without heterogeneity (Cochran's Q
188	statistic p>0.05) (Figure 2, Supplemental Table 4).
189	
190	There was no genetic association between the BCAA predictors and type 2 diabetes by IVW for
191	valine (beta=0.17 change in log-odds per standard deviation change in valine, [95% CI, -0.28 -
192	0.62], p=0.45), leucine (beta=0.19 [-0.30 - 0.68] p=0.45) or isoleucine (beta=0.02 [-0.54 - 0.59],
193	p=0.94) by the IVW method (Figure 3). Similar results were seen in sensitivity analyses using
194	the leave-one-out, MR-Egger and weighted median methods (Supplementary Figure 1,
195	Supplemental Table 5). There was significant heterogeneity (Cochran's Q statistic p<0.05) for
196	each association, but the MR-Egger intercept values were not significant (p>0.05), and outlier
197	removal by the MR-PRESSO method did not identify significant distortion (p>0.05) in the effect
198	estimates (Supplemental Table 5).
199	
200	We next constructed instrumental variables for type 2 diabetes (n=95 SNPs) to determine
201	whether the type 2 diabetes was associated with altered BCAA levels. There were significant
202	positive associations with each BCAA (valine: beta=0.08 per standard deviation change in levels
203	per log-odds change in type 2 diabetes, [95% CI: $0.05 - 0.10$], p=1.8x10 ⁻⁹), (leucine: beta= 0.06
204	[0.04 - 0.09], p=4.5x10 ⁻⁸) and isoleucine (beta= 0.06 [0.04 - 0.08], p=2.8x10 ⁻⁸) (Figure 5 ,
205	Supplemental Table 6). Sensitivity analyses showed consistent results. Similar significant
206	positive associations were seen when testing associations with with BCAA levels measured in
207	the KORA study (Supplementary Figure 2, Supplemental Table 7). We tested associations

208	with BCAA levels in METSIM. In this set, all participants with prevalent or incident type 2
209	diabetes were excluded from the BCAA GWAS, which would be expected to attenuate or
210	eliminate an association with type 2 diabetes if the association was due to this disease. As
211	expected, while the directions for all associations were consistent with those observed in the UK
212	Biobank and KORA sets, they were not significant for valine and leucine and nominally
213	significant for isoleucine (p=0.03) (Supplementary Figure 3, Supplemental Table 8).
214	
215	The SNPs associated with BCAA levels are associated with insulin regulation and adiposity,
216	suggesting that the BCAAs may be up-stream of these traits. To test this hypothesis, we
217	constructed instrumental variables for fasting insulin levels (n=34 SNPs) and BMI (n=69 SNPs).
218	Similar to type 2 diabetes, there were significant positive associations with each phenotype and
219	each BCAA (Supplemental Figure 4, Supplemental Table 9). In sensitivity analyses the MR-
220	Egger results for fasting insulin demonstrated discordant results with wide confidence intervals
221	(Supplemental Table 9). However, the intercept p-values were not significant. MR-PRESSO
222	analysis did not show significant distortion (p>0.05) after removing outliers. It has previously
223	been observed the MR-Egger can produce unreliable discordant estimates with wide confidence
224	intervals in the presence of SNPs with a direct effects on the outcome. ^{28,32} This was the case
225	here, as, for instance, excluding 2 outlying SNPs identified by MR-PRESSO brought the MR-
226	Egger estimate (0.61) in line with the IVW (0.60) and weighted median (0.70) estimates for
227	leucine. In sum, these results suggest that BCAA levels are higher with higher type 2 diabetes
228	risk, fasting insulin levels and BMI.Multivariable MR was used to determine whether the
229	associations with type 2 diabetes was independent of BMI and levels. Type 2 diabetes was
230	associated with each BCAA, independent of BMI and fasting insulin levels (Figure 5,

231 Supplemental Table 8). However, associations between BMI and the BCAAs were not

significant (p>0.05) after adjustment for type 2 diabetes.

- 233
- 234

235 **DISCUSSION**

236 We constructed and validated genetic instruments for the BCAAs valine, leucine and isoleucine

and tested whether they were associated with type 2 diabetes using standard MR approaches.

238 While the genetic instruments robustly associated with positive control phenotypes, they did not

associate with type 2 diabetes. This contrasts with a prior MR study which demonstrated

associations for each BCAA.¹² In line with prior studies, we found that fasting insulin and BMI

241 were positively associated with BCAA levels.^{13,33} In addition, we found that genetic instruments

for type 2 diabetes were also robustly associated with BCAA levels, suggesting that the BCAAs

are biomarkers, rather than causal mediators of type 2 diabetes. Multivariable MR suggested that

the associations with BMI are likely mediated through increasing type 2 diabetes risk.

245

246 We did not replicate findings from a prior study that observed associations between genetic instruments of the BCAAs and type 2 diabetes.¹² There are important differences between that 247 248 study and this one. The BCAA predictors in that study were heavily weighted with SNPs in high 249 linkage-disequilibrium around the *PPMK1* gene, whose gene product regulates catabolism of 250 each of the BCAAs. Their value and leucine predictors only used SNPs around that gene locus, 251 and thus were only testing for an association based on a single genetic mechanism. Favoring an 252 association was the fact that there was a suggestive association around the PPMK1 gene in their 253 type 2 diabetes GWAS and the high representation of SNPs in high LD in this region. We did not

254	observe a type 2 diabetes association at the <i>PPMK1</i> locus in the DIAGRAM Consortium GWAS
255	data set. Their isoleucine predictor additionally included SNPs around the TRMT61A, CBLN1
256	and DDX19A, but not GCKR. We did not observe associations and found directional
257	inconsistency between the BCAAs and their lead SNPs around the TRMT61A and CBLN1 genes
258	in the UK Biobank and METSIM cohorts. Thus, we could not replicate their findings due to
259	these non-replicating SNP associations related to isoleucine and type 2 diabetes.
260	
261	
262	We used a larger set of SNPs measuring diverse genetic mechanisms associated with levels of
263	BCAAs in plasma than prior studies. In general, MR results are most robust when the genetic
264	instruments measure a broad set of independent genetic mechanisms associated with an
265	exposure, as this decreases the likelihood of spurious associations that can result from examining
266	a small number of genetic loci. ²⁶ Attesting to the validity of the BCAA genetic instruments, we
267	found that the SNP effect sizes corresponded to those measured in an independent cohort. When
268	testing for the type 2 diabetes association, we employed a two-sample design to reduce the
269	chance of identifying associations based on reverse causality and we performed a number of
270	sensitivity analyses to ensure that outlying SNPs were not obscuring an association. Thus, we
271	believe these findings more accurately describe the genetic relationship between the BCAAs and

273

272

type 2 diabetes.

The SNPs associated with the BCAAs highlight a number of genetic mechanisms influencing
circulating BCAA levels, many of which have functions within the mitochondria. In addition to *PPMK1*, the protein product of *BCAT2* transanimates the BCAAs to α-ketoacids while

converting α -ketoglutarate (α KG) to glutamate.³⁴ The gene products of *GLUD1*, *PRODH* and 277 GLS2 also impact glutamate metabolism.³⁵ PCCB contributes to BCAA breakdown by 278 catabolism of propionyl-CoA.³⁶ Several genes are related to glucose regulation, including *GCKR* 279 280 which inhibits glucose metabolism by glucokinase, SLC2A4 (GLUT4) which allows glucose 281 entry into cells in response to insulin signaling, and glucose signaling including MLXIP which modulates transcription in response to intracellular glucose levels.³⁷ IRS1 and GRB14 both 282 regulate signaling through the insulin receptor.³⁸ There were also genes associated to adiposity 283 284 including HNF4G, a transcription factor found to be associated with BMI in GWAS studies and *RNL3*, which may have a role in appetite regulation.³⁹⁻⁴¹ There were also SNPs located at loci 285 286 that identified genomic regions where the link to BCAAs was not clear including SNPs near MOK, DDX19A-DT, SUOX⁴² and DHODH. 287

288

289 Collectively, the SNP associations support the hypothesis that BCAA levels are influenced not 290 only by gene products directly involved in BCAA catabolism, but also physiological processes related to insulin signaling, glucose regulation and adiposity.⁴³ Consistently, we found that 291 292 genetic instruments related to BMI, fasting insulin levels and type 2 diabetes associated with 293 each BCAA. The associations were in a positive direction, consistent with well-established 294 epidemiological observations. For leucine and isoleucine, the BMI association was not 295 significant after multivariable adjustment, and remained only nominally associated with valine. 296 These results suggest that the BMI association was most likely related to the influences of 297 adiposity on insulin resistance and penetrance of type 2 diabetes.⁴⁴ 298

299	There are limitations to the current study. False positive associations can arise from the use of
300	weak genetic instruments or the use of pleiotropic SNPs that associate with a risk factor through
301	mechanisms unrelated to the exposure. To mitigate this possibility, we used a range of sensitivity
302	analyses to ensure that associations were consistent across a range of assumptions. These
303	findings also conflict with some epidemiological and experimental data, which could suggest
304	that non-genetically determined BCAA levels may contribute to type 2 diabetes and insulin
305	resistance through mechanisms not captured by these studies. The analyses also relied on
306	existing data that predominantly represents individuals of European ancestries, which limits
307	generalization to other ancestry groups.
308	
309	In summary, we did not find evidence supporting a causal role for BCAAs on type 2 diabetes
310	risk. Rather, these data support the hypothesis that the BCAAs levels are increased as a
311	consequence of diabetes and insulin resistance.
312	
313	
314	AUTHOR CONTRIBUTIONS
315	JDM and MS had full access to all data and takes responsibility for the integrity of the data and
316	analysis. JDM and JFF provided substantial contributions to the design of the study. MS
317	performed the primary analysis of the BioVU data. MS and DA made substantial contributions to
318	the acquisition of data. JDM, MS and JFF wrote the first draft of the manuscript. All coauthors
319	critically reviewed the manuscript for important intellectual content, provided final approval of
320	the version to be published, and agree to be accountable for some or all aspects of the work
321	presented.

322 DECLARATION OF INTERESTS

- 323 None.
- 324

325 FUNDING SOURCES

- 326 This work was supported by the NIH R01 HL142856 (to JFF and JDM). JFF is also supported by
- 327 R01 DK117144. MB is supported by T32 HG008341.
- 328

329 **REFERENCES**

- Branched Chain Amino Acids: Beyond Nutrition Metabolism PubMed [Internet]. [cited
 2023 Apr 20];Available from: https://pubmed.ncbi.nlm.nih.gov/29570613/
- Felig P, Marliss E, Cahill GF. Plasma amino acid levels and insulin secretion in obesity. *N Engl J Med.* 1969;281:811–816.
- Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS,
 Jacques PF, Fernandez C, et al. Metabolite profiles and the risk of developing diabetes. *Nat. Med.* 2011;17:448–453.
- Floegel A, Stefan N, Yu Z, Mühlenbruch K, Drogan D, Joost H-G, Fritsche A, Häring H-U,
 Hrabě de Angelis M, Peters A, et al. Identification of serum metabolites associated with
 risk of type 2 diabetes using a targeted metabolomic approach. *Diabetes*. 2013;62:639–648.
- McCormack SE, Shaham O, McCarthy MA, Deik AA, Wang TJ, Gerszten RE, Clish CB,
 Mootha VK, Grinspoon SK, Fleischman A. Circulating branched-chain amino acid
 concentrations are associated with obesity and future insulin resistance in children and
 adolescents. *Pediatr Obes*. 2013;8:52–61.
- Merino J, Leong A, Liu C-T, Porneala B, Walford GA, von Grotthuss M, Wang TJ,
 Flannick J, Dupuis J, Levy D, et al. Metabolomics insights into early type 2 diabetes
 pathogenesis and detection in individuals with normal fasting glucose. *Diabetologia*.
 2018;61:1315–1324.
- Hamley S, Kloosterman D, Duthie T, Dalla Man C, Visentin R, Mason SA, Ang T,
 Selathurai A, Kaur G, Morales-Scholz MG, et al. Mechanisms of hyperinsulinaemia in
 apparently healthy non-obese young adults: role of insulin secretion, clearance and action
 and associations with plasma amino acids. *Diabetologia*. 2019;62:2310–2324.
- Julkunen H, Cichońska A, Tiainen M, Koskela H, Nybo K, Mäkelä V, Nokso-Koivisto J,
 Kristiansson K, Perola M, Salomaa V, et al. Atlas of plasma NMR biomarkers for health
 and disease in 118,461 individuals from the UK Biobank. *Nat Commun.* 2023;14:604.
- Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian
 randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med.* 2008;27:1133–1163.
- Ebrahim S, Davey Smith G. Mendelian randomization: can genetic epidemiology help
 redress the failures of observational epidemiology? *Hum. Genet.* 2008;123:15–33.
- Biswas D, Duffley L, Pulinilkunnil T. Role of branched-chain amino acid-catabolizing
 enzymes in intertissue signaling, metabolic remodeling, and energy homeostasis. *FASEB J*.
 2019;33:8711–8731.
- Lotta LA, Scott RA, Sharp SJ, Burgess S, Luan J, Tillin T, Schmidt AF, Imamura F,
 Stewart ID, Perry JRB, et al. Genetic Predisposition to an Impaired Metabolism of the

- Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation
 Analysis. *PLoS Med*. 2016;13:e1002179.
- Mahendran Y, Jonsson A, Have CT, Allin KH, Witte DR, Jørgensen ME, Grarup N,
 Pedersen O, Kilpeläinen TO, Hansen T. Genetic evidence of a causal effect of insulin
 resistance on branched-chain amino acid levels. *Diabetologia*. 2017;60:873–878.
- 370 14. Neinast M, Murashige D, Arany Z. Branched Chain Amino Acids. *Annu Rev Physiol*.
 371 2019;81:139–164.
- Richardson TG, Leyden GM, Wang Q, Bell JA, Elsworth B, Davey Smith G, Holmes MV.
 Characterising metabolomic signatures of lipid-modifying therapies through drug target
 mendelian randomisation. *PLoS Biol*. 2022;20:e3001547.
- Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon
 A, Morales J, Mountjoy E, Sollis E, et al. The NHGRI-EBI GWAS Catalog of published
 genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* 2018;
- 379 17. Yin X, Chan LS, Bose D, Jackson AU, VandeHaar P, Locke AE, Fuchsberger C, Stringham
 380 HM, Welch R, Yu K, et al. Genome-wide association studies of metabolites in Finnish men
 381 identify disease-relevant loci. *Nat Commun.* 2022;13:1644.
- 18. Shin S-Y, Fauman EB, Petersen A-K, Krumsiek J, Santos R, Huang J, Arnold M, Erte I,
 Forgetta V, Yang T-P, et al. An atlas of genetic influences on human blood metabolites. *Nat. Genet.* 2014;46:543–550.
- Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, Payne AJ,
 Steinthorsdottir V, Scott RA, Grarup N, et al. Fine-mapping type 2 diabetes loci to singlevariant resolution using high-density imputation and islet-specific epigenome maps. *Nat. Genet.* 2018;50:1505–1513.
- 20. Lagou V, Mägi R, Hottenga J-J, Grallert H, Perry JRB, Bouatia-Naji N, Marullo L, Rybin
 D, Jansen R, Min JL, et al. Sex-dimorphic genetic effects and novel loci for fasting glucose
 and insulin variability. *Nat Commun.* 2021;12:24.
- Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S,
 Buchkovich ML, Yang J, et al. Genetic studies of body mass index yield new insights for
 obesity biology. *Nature*. 2015;518:197–206.
- Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
 annotation of genetic associations with FUMA. *Nat Commun.* 2017;8:1826.
- Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the
 comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* 2009;37:1–13.
- Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene
 lists using DAVID bioinformatics resources. *Nat Protoc*. 2009;4:44–57.

25. de Leeuw C, Savage J, Bucur IG, Heskes T, Posthuma D. Understanding the assumptions 401 402 underlying Mendelian randomization. Eur J Hum Genet. 2022;30:653-660. 403 26. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple 404 genetic variants using summarized data. Genet. Epidemiol. 2013;37:658-665. 405 27. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet 406 407 Epidemiol. 2016;40:304-314. 408 28. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the 409 MR-Egger method. Eur J Epidemiol. 2017;32:377-389. 410 29. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing 411 Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46:1734-412 1739. 413 30. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in 414 causal relationships inferred from Mendelian randomization between complex traits and 415 diseases. Nat Genet. 2018;50:693-698. 416 Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic 31. 417 genetic variants to estimate causal effects. Am. J. Epidemiol. 2015;181:251–260. 418 32. Gill D, Cameron AC, Burgess S, Li X, Doherty DJ, Karhunen V, Abdul-Rahim AH, 419 Taylor-Rowan M, Zuber V, Tsao PS, et al. Urate, Blood Pressure, and Cardiovascular 420 Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials. 421 Hypertension. 2021;77:383–392. 422 33. Wang Q, Holmes MV, Davey Smith G, Ala-Korpela M. Genetic Support for a Causal Role 423 of Insulin Resistance on Circulating Branched-Chain Amino Acids and Inflammation. 424 Diabetes Care. 2017;40:1779-1786. 425 34. Ichihara A. Isozyme patterns of branched-chain amino acid transaminase during cellular differentiation and carcinogenesis. Ann NY Acad Sci. 1975;259:347-354. 426 427 35. Hewton KG, Johal AS, Parker SJ. Transporters at the Interface between Cytosolic and 428 Mitochondrial Amino Acid Metabolism. Metabolites. 2021;11:112. 429 36. Wongkittichote P, Ah Mew N, Chapman KA. Propionyl-CoA carboxylase - A review. Mol 430 Genet Metab. 2017;122:145-152. 431 37. Kaadige MR, Looper RE, Kamalanaadhan S, Ayer DE. Glutamine-dependent anapleurosis 432 dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Proc 433 Natl Acad Sci U S A. 2009;106:14878-14883. 434 38. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin 435 receptor signalling. Nat Rev Mol Cell Biol. 2018;19:31-44.

436 437 438	39.	Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, Lindgren CM, Luan J, Mägi R, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. <i>Nat. Genet.</i> 2010;42:937–948.
439 440 441	40.	McGowan BMC, Stanley SA, Smith KL, White NE, Connolly MM, Thompson EL, Gardiner JV, Murphy KG, Ghatei MA, Bloom SR. Central relaxin-3 administration causes hyperphagia in male Wistar rats. <i>Endocrinology</i> . 2005;146:3295–3300.
442 443	41.	Ghattas MH, Mehanna ET, Mesbah NM, Abo-Elmatty DM. Relaxin-3 is associated with metabolic syndrome and its component traits in women. <i>Clin Biochem</i> . 2013;46:45–48.
444	42.	Kappler U, Enemark JH. Sulfite-oxidizing enzymes. J Biol Inorg Chem. 2015;20:253–264.
445 446 447 448 449	43.	Doestzada M, Zhernakova DV, C L van den Munckhof I, Wang D, Kurilshikov A, Chen L, Bloks VW, van Faassen M, Rutten JHW, Joosten LAB, et al. Systematic analysis of relationships between plasma branched-chain amino acid concentrations and cardiometabolic parameters: an association and Mendelian randomization study. <i>BMC Med.</i> 2022;20:485.
450 451	44.	Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. <i>Nature</i> . 2006;444:840–846.
452		

TABLES

- **Table 1.** Genomic loci and candidate genes associated with circulating valine, leucine or
- 456 isoleucine levels.

Chromosome: Position (Hg37)	Lead SNP(s)	Lead candidate gene(s) ¹	Function ²
2:27730940	Val: rs1260326 Leu: rs1260326 Ile: rs1260326	GCKR	Inhibits glucokinase in liver and pancreatic islet cells.
2:65219030	Val: rs2007061	SLC1A4	Sodium-dependent neutral amino acid transporter for alanine, serine, cysteine, and threonine.
2:165501927 - 2:165528876	Val: rs13389219 Leu: rs5835988 Ile: rs5835988	GRB14	Interacts with insulin receptors and inhibits insulin receptor signaling.
2:227108446	Val: rs2943652 Leu: rs2943652	IRS1	Transmits signal between the insulin receptor and phosphoinositide 3-kinase.
3:136328270	Val: rs1471740 Leu: rs1471740	РССВ	Breaks down amino acids including isoleucine and valine.
4:88920985	Val: rs10018448 Leu: rs114796149, rs10018448 Ile: rs114796149	PPMIK	Activates branched chain α -ketoacid dehydrogenase complex that catalyzes the first step in the BCAA metabolism.
8:76443463 - 8:76454025	Leu: rs2977929 Ile: rs2941456	HNF4G	Enables DNA-binding transcription activator activity. Associated with BMI by GWAS.
10:88820592	Val: rs17096421	GLUD1	Mitochondrial matrix enzyme that catalyzes the oxidative deamination of glutamate to alpha-ketoglutarate and ammonia.
12:56393337	Val: rs1081975 Leu: rs1081975	SUOX	Breaks down sulfur-containing amino acids.
12:56861458 - 12:56865056	Val: rs2638315 Leu: rs2638315 Ile: rs7302925	GLS2	Catalyzes the hydrolysis of glutamine to glutamate and ammonia.
12:122607112	Val: rs12368387	MLXIP (MONDOA)	Transcriptional activation of glycolitic target genes in response to cellular glucose levels.
14:102718052	Val: rs2274815	WDR20, MOK, ZNF839	Multiple. Lead SNP intronic in MOK.

16:70270907 - 16:70368909	Val: rs12325419 Leu: rs35452938 Ile: rs12325419	Multiple, including DDX19A- DT and DDX19B	Multiple. Intronic in DDX19A-DT and 3' UTR in DDX19B. DDX19A identified on prior isoleucine GWAS.
16:72149923	Leu: rs9930957	DHODH,TX NL4B,HP,H PR,DHX38, PMFBP1	Multiple.
17:7185779	Val: rs117643180 Leu: rs117643180 Ile: rs117643180	SLC2A4 (GLUT4)	Insulin-regulated facilitative membrane glucose transport into cells.
17:79636653	Val: rs62080209	SLC25A10 (DIC)	Translocates small metabolites (e.g. malate, succinate) across the mitochondrial membrane for metabolic processes including the TCA cycle and fatty acid synthesis.
19:14139004	Leu: rs1982632	RLN3	Insulin-superfamily hormone regulating appetite, food intake, and weight gain.
19:49300431 - 19:49317459	Val: rs35230038, rs117048185 Leu: rs4801776 Ile: rs71179052	BCAT2	Mitochondrial branched chain aminotransferase that catalyzes production of the BCAAs.
22:18915282 - 22:18915347	Val: rs2238732 Leu: rs5747934	PRODH	Mitochondrial protein that catalyzes the first step in proline degradation.

458

459 Footnotes:

460 1. Lead candidate genes shown were selected based on their proximity to lead the lead SNP,


461 eQTL analyses and known relevance of cellular functions to BCAA metabolism.

462 2. Known cellular functions for loci where a single lead candidate gene is identified.

464 FIGURE LEGENDS


465

- 466 Figure 1: Cellular functions of proteins for genes associated with circulating valine, leucine
- 467 **and isoleucine levels.** Genes located near lead SNPs are highlighted in red.



472 Figure 2: Associations between SNP instruments for the BCAAs and validation

- 473 **phenotypes.** (A-C) Scatter plots showing comparing the GWAS effect sizes between the valine
- 474 (n=13 SNPs), leucine (n=13 SNPs) and isoleucine SNP (n=7 SNPs) genetic instruments
- 475 identified in the UK Biobank cohort and their corresponding amino acid in the METSIM cohort.
- 476 The lines represent the association based on the IVW method. (D) Summary of associations from
- 477 MR analyses testing the association between the genetic instruments in UK Biobank and their
- 478 corresponding amino acid level in METSIM. IVW=inverse variance weighted method.
- 479




D	Exposure		Beta (95% CI)
	Valine		
	IVW		1.00 (0.77 - 1.24)
	MR-Egger		1.17 (0.66 - 1.67)
	Weighted median	-•-	1.09 (0.77 - 1.40)
	Leucine		
	IVW		1.11 (0.77 - 1.45)
	MR-Egger	_ •	1.52 (0.80 - 2.25)
	Weighted median		1.29 (0.94 - 1.64)
	Isoleucine		
	IVW		1.49 (1.17 - 1.81)
	MR-Egger	-	1.93 (0.93 - 2.93)
	Weighted median		1.51 (1.10 - 1.92) 3

481 Figure 3: Associations between SNP instruments for the BCAAs and type 2 diabetes. (A-C)


482 Scatter plots showing comparing the associations between the valine, leucine and isoleucine SNP
483 genetic instruments and with type 2 diabetes. The lines represent the association based on the
484 IVW method. (D) Summary of associations from MR analyses testing the association between
485 the genetic instruments for each BCAA and type 2 diabetes. IVW=inverse variance weighted
486 method.

487



489 Figure 4: Associations between SNP instruments for metabolic phenotypes and BCAAs. (A-

- 490 C) Scatter plots showing of the associations between genetic instruments for type 2 diabetes
- 491 (n=95 SNPs) and valine, leucine and isoleucine. The lines represent the association based on the
- 492 IVW method. (D) Forest plot summarizing the associations by the inverse variance weighted
- 493 (IVW) method between genetic instruments for type 2 diabetes, fasting insulin (n=34 SNPs) and
- 494 body mass index (BMI) (n=69 SNPs) and valine, leucine and isoleucine.
- 495



D	Exposure/ Outcome		Beta (95% CI)
	T2D		
	Valine	•	0.08 (0.05 - 0.10)
	Leucine	•	0.06 (0.04 - 0.09)
	Isoleucine	•	0.06 (0.04 - 0.08)
	Fasting insulin		
	Valine	e	0.44 (0.13 - 0.76)
	Leucine		0.46 (0.17 - 0.76)
	Isoleucine	•	0.41 (0.12 - 0.69)
	BMI		
	Valine	-	0.16 (0.11 - 0.21)
	Leucine	-	0.11 (0.06 - 0.16)
	Isoleucine		0.11 (0.07 - 0.16)

497 Figure 5: Multivariable MR associations between type 2 diabetes and BCAAs. Forest plots

498 summarizing the multivariable MR associations by the inverse variance weighted (IVW) method

499 between genetic instruments for type 2 diabetes and valine, leucine and isoleucine, adjusted for


500 either BMI or fasting insulin.

501


Outcome/ Exposure		Beta (95% CI)	
Valine			
Type 2 DM	-	0.09 (0.07 - 0.11)
BMI		0.06 (-0.01 - 0.1	2)
Type 2 DM	-	0.08 (0.06 - 0.10))
Fasting ins.	 	 0.34 (0.17 - 0.51)
Leucine			
Type 2 DM	-	0.07 (0.05 - 0.09))
BMI		0.02 (-0.04 - 0.0	9)
Type 2 DM	-	0.07 (0.05 - 0.09))
Fasting ins.		 0.34 (0.19 - 0.50))
Isoleucine			
Type 2 DM	-	0.07 (0.05 - 0.09))
BMI	+ -	0.04 (-0.02 - 0.0	9)
Type 2 DM	-	0.07 (0.05 - 0.09))
Fasting ins.	0 0.2	0.29 (0.13 - 0.45 0.4	5)

503


502



Supplementary Figure 1. Summary of a leave-one-out analysis for the associations between genetic instruments for (A) valine, (B) leucine and (C) isoleucine and type 2 diabetes. Each figures shows the IVW estimate (95% CI) after exclusion of the indicated SNP. Note that the name of the closest gene was substituted for the SNP name, when available.




Supplementary Figure 2. Associations between SNP instruments for type 2 diabetes and BCAAs measured in the KORA population. (A-C) Scatter plots showing of the associations between genetic instruments for type 2 diabetes (n=90 SNPs) and valine, leucine and isoleucine. The lines represent the association based on the IVW method. (D) Forest plot summarizing the associations by the inverse variance weighted (IVW) method between genetic instruments for type 2 diabetes and valine, leucine.



Supplementary Figure 3. Associations between SNP instruments for type 2 diabetes and BCAAs measured in the METSIM population. (A-C) Scatter plots showing of the associations between genetic instruments for type 2 diabetes (n=95 SNPs) and valine, leucine and isoleucine. The lines represent the association based on the IVW method. (D) Forest plot summarizing the associations by the inverse variance weighted (IVW) method between genetic instruments for type 2 diabetes and valine, leucine.

Fasting insulin



Supplementary Figure 4. Associations between SNP instruments for fasting insulin or BMI, and the BCAAs measured in the UK biobank population. Scatter plots showing of the associations between genetic instruments for fasting insulin (top panels) and BMI (bottom panels) and each BCAA. The lines represent the association based on the IVW method.